Media coverage
9
Media coverage
Title Bayer’s KERENDIA® (finerenone) Receives Updated Label to Include Findings From Phase III FIGARO-DKD Cardiovascular Outcomes Study in Patients With Chronic Kidney Disease and Type 2 Diabetes Media name/outlet Morningstar.com Country/Territory United States Date 1/09/22 URL https://www.morningstar.com/news/business-wire/20220901005853/bayers-kerendia-finerenone-receives-updated-label-to-include-findings-from-phase-iii-figaro-dkd-cardiovascular-outcomes-study-in-patients-with-chronic-kidney-disease-and-type-2-diabetes Persons Sameer Bansilal Title Bayer’s KERENDIA® (finerenone) Receives Updated Label to Include Findings From Phase III FIGARO-DKD Cardiovascular Outcomes Study in Patients With Chronic Kidney Disease and Type 2 Diabetes Media name/outlet Business Wire Country/Territory United States Date 1/09/22 URL www.businesswire.com/news/home/20220901005853/en/Bayer%E2%80%99s-KERENDIA%C2%AE-finerenone-Receives-Updated-Label-to-Include-Findings-From-Phase-III-FIGARO-DKD-Cardiovascular-Outcomes-Study-in-Patients-With-Chronic-Kidney-Disease-and-Type-2-Diabetes/?feedref=JjAwJuNHiystnCoBq_hl-RLXHJgazfQJNuOVHefdHP-D8R-QU5o2AvY8bhI9uvWSD8DYIYv4TIC1g1u0AKcacnnViVjtb72bOP4-4nHK5ieT3WxPE8m_kWI77F87CseT Persons Sameer Bansilal Title Bayer's KERENDIA® (finerenone) Receives Updated Label to Include Findings From Phase III FIGARO-DKD Cardiovascular Outcomes Study in Patients With Chronic Kidney Disease and Type 2 Diabetes Media name/outlet Business Wire Country/Territory United States Date 1/09/22 Persons Sameer Bansilal Title Bayer’s KERENDIA® (finerenone) Receives Updated Label to Include Findings From Phase III FIGARO-DKD Cardiovascular Outcomes Study in Patients With Chronic Kidney Disease and Type 2 Diabetes Media name/outlet Street Insider Country/Territory United States Date 1/09/22 URL https://www.streetinsider.com/Press+Releases/Bayer%E2%80%99s+KERENDIA%C2%AE+%28finerenone%29+Receives+Updated+Label+to+Include+Findings+From+Phase+III+FIGARO-DKD+Cardiovascular+Outcomes+Study+in+Patients+With+Chronic+Kidney+Disease+and+Type+2+Diabetes/20543186.html Persons Sameer Bansilal Title Bayer’s KERENDIA® (finerenone) Receives Updated Label to Include Findings From Phase III FIGARO-DKD Cardiovascular Outcomes Study in Patients With Chronic Kidney Disease and Type 2 Diabetes Media name/outlet Yahoo! News Country/Territory United States Date 1/09/22 URL https://www.yahoo.com/now/bayer-kerendia-finerenone-receives-updated-221500454.html Persons Sameer Bansilal Title Bayer’s KERENDIA® (finerenone) Receives Updated Label to Include Findings From Phase III FIGARO-DKD Cardiovascular Outcomes Study in Patients With Chronic Kidney Disease and Type 2 Diabetes Media name/outlet ADVFN US Country/Territory United States Date 1/09/22 URL https://www.advfn.com/p.php?pid=nmona&article=88970689 Persons Sameer Bansilal Title Bayer’s KERENDIA® (finerenone) Receives Updated Label to Include Findings From Phase III FIGARO-DKD Cardiovascular Outcomes Study in Patients With Chronic Kidney Disease and Type 2 Diabetes Media name/outlet Spoke.com Country/Territory United States Date 1/09/22 URL https://www.spoke.com/press_releases/6311332b0093f07b07000562 Persons Sameer Bansilal Title Bayer’s KERENDIA® (finerenone) Receives Updated Label to Include Findings From Phase III FIGARO-DKD Cardiovascular Outcomes Study in Patients With Chr Media name/outlet Acrofan Date 1/09/22 URL https://us.acrofan.com/detail.php?number=717086 Persons Sameer Bansilal Title Bayer’s KERENDIA® (finerenone) Receives Updated Label to Include Findings From Phase III FIGARO-DKD Cardiovascular Outcomes Study in Patients With Chronic Kidney Disease and Type 2 Diabetes Media name/outlet VB Profiles Country/Territory United States Date 1/09/22 URL https://www.vbprofiles.com/press_releases/6311332e4565bb001bd09784 Persons Sameer Bansilal